“Biogen has been, and continues to be, committed to working with all stakeholders to ensure SPINRAZA is available as an option for people with SMA to treat this devastating disease,” said David Henderson, the managing director of Biogen Australia and New Zealand.
Expanded funding of SPINRAZA for treatment of pre-symptomatic SMA babies
March 4, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Moderna expands support for early career Australian mRNA researchers
May 7, 2026 - - Latest News -
The review is formally over. Why is it restarting?
May 7, 2026 - - Latest News -
AI screening tool gives pathologists 'super' vision to detect hidden cancer
May 7, 2026 - - Latest News -
Australian company celebrated in centenary project on royal and parliamentary leadership
May 6, 2026 - - Latest News -
La Trobe launches REACH program to fight antimicrobial resistance
May 6, 2026 - - Latest News -
If the imperative is international comparison, why limit it to these definitions?
May 5, 2026 - - Latest News -
Therapy funded three years after the 'clunky' and 'preventable deaths' admission
May 5, 2026 - - Latest News
